Hypogammaglobulinaemia in adults (found on electrophoresis)
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
Found without warning signs: first-line tests
Laboratory tests
- Serum immunoglobulins (IgG, IgA and IgM)
- Serum protein immunofixation
- FBC
- Urine protein:creatinine ratio (spot sample)
- Serum creatinine with eGFR
- HIV serology
- Anti-tetanus antibodies (vaccine response)
Repeat later
- Serum immunoglobulins (IgG, IgA and IgM): repeat (if the first result is low, with no obvious cause)if needednon-French guidelineA primary immunodeficiency is considered only if IgG and IgA are low on at least two occasions, secondary causes having been excluded [2].
Do not order
- IgG subclasses: of interest only if a primary immunodeficiency is suspected, not as a routine [3]; indicated mainly for recurrent infections despite normal IgG [1].
- Vaccine serologies other than tetanus (pneumococcus, Haemophilus) in the community: not reimbursed in community laboratories in France; they are a matter for the specialist centre [1].
- T, B, NK lymphocyte phenotyping as first-line test: a second-line test, after hypogammaglobulinaemia has been confirmed [1].
Proteinuria, tumour syndrome, cytopenia or lymphocytosis: rule out a haematological malignancy
Laboratory tests (rapid)
- FBC
- Serum immunoglobulins (IgG, IgA and IgM)
- Serum protein immunofixation
- Urine protein:creatinine ratio (spot sample)
- Serum creatinine with eGFR
- Serum calcium
- LDH
- Urine protein electrophoresisif neededProteinuria present (Bence Jones testing is done only above 50 mg/L according to the NABM [4]): proteinuria without albuminuria with hypogammaglobulinaemia suggests light-chain myeloma [3].
- Urine immunofixation (Bence Jones proteinuria)if neededProteinuria present (Bence Jones testing is done only above 50 mg/L according to the NABM [4]): proteinuria without albuminuria with hypogammaglobulinaemia suggests light-chain myeloma [3].
- Blood lymphocyte immunophenotypingif neededLymphocytosis: suspected chronic lymphocytic leukaemia [3].
- Serum free kappa and lambda light chains (if light-chain myeloma suspected)if needednon-French guidelineNICE pairs them with electrophoresis to confirm a monoclonal component [11] and requests them from primary care onwards after age 60 for persistent bone pain or unexplained fracture [12]. The HAS reserves their prescription for the specialist, the technique not being listed in the French laboratory fee schedule (NABM) [13], and it is not established that they should replace the search for proteinuria [3]. An electrophoresis without a narrow peak does not rule out light-chain myeloma [13].
Before and on rituximab (anti-CD20)
Before the first infusion
- Serum immunoglobulins (IgG, IgA and IgM)
Sources (15)
- Centre de référence des déficits immunitaires héréditaires (CEREDIH), filière MaRIH. Protocole national de diagnostic et de soins (PNDS) : déficits immunitaires héréditaires. Décembre 2022, mis en ligne par la HAS en avril 2023 (avec synthèse pour le médecin traitant).
- European Society for Immunodeficiencies (ESID) Registry Working Party. Working definitions for clinical diagnosis of inborn errors of immunity, version de novembre 2019 (publiées : Seidel MG et al. J Allergy Clin Immunol Pract. 2019;7(6):1763-1770).
- Frenzel L. L'hypogammaglobulinémie : que faut-il en retenir ? Feuillets de Biologie. 2017;(334):5-11 (document mis en ligne par les laboratoires Maymat).
- Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : note de présentation (règle 4), actes 1103, 1571, 1619.
- Otani IM, Lehman HK, Jongco AM, et al. Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees. J Allergy Clin Immunol. 2022;149(5):1525-1560.
- Agence européenne des médicaments. MabThera (rituximab) : résumé des caractéristiques du produit (information produit EPAR), rubriques 4.4 et 4.8, consulté le 11 octobre 2026.
- Bonilla FA, Barlan I, Chapel H, et al. International Consensus Document (ICON): Common Variable Immunodeficiency Disorders. J Allergy Clin Immunol Pract. 2016;4(1):38-59.
- Wijetilleka S, Jayne DR, Mukhtyar C, et al. Recommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted therapies in autoimmune rheumatic diseases. Rheumatology (Oxford). 2019;58(5):889-896.
- National Blood Authority (Australie). Criteria for the clinical use of immunoglobulin in Australia : Secondary hypogammaglobulinaemia unrelated to haematological malignancy or haemopoietic stem cell transplant (HSCT). Consulté le 30 octobre 2026 (fiche 2722 ; version non indiquée sur le document).
- Patel SY, Carbone J, Jolles S. The Expanding Field of Secondary Antibody Deficiency: Causes, Diagnosis, and Management. Front Immunol. 2019;10:33.
- National Institute for Health and Care Excellence. Myeloma: diagnosis and management. NICE guideline NG35, publiée le 10 février 2016, mise à jour le 25 octobre 2018 (recommandations 1.2.1 à 1.2.3).
- National Institute for Health and Care Excellence. Suspected cancer: recognition and referral. NICE guideline NG12, juin 2015, mise à jour du 15 avril 2026 (recommandation 1.10.4).
- Haute Autorité de santé. Fiche mémo : Quand prescrire une électrophorèse des protéines sériques (EPS) et conduite à tenir en cas d’une immunoglobuline monoclonale. Janvier 2017.
- Hughes PR, Shreve NE, Bloecher PA. Multiple Myeloma: Diagnosis and Treatment. Am Fam Physician. 2026;113(3):244-253.
- Zorginstituut Nederland. Farmacotherapeutisch Kompas : rituximab (Pays-Bas). Consulté le 30 octobre 2026.